Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Notes Payables (2022 - 2025)

Dexcom (DXCM) has disclosed Notes Payables for 4 consecutive years, with $1.2 billion as the latest value for Q3 2025.

  • Quarterly Notes Payables changed N/A to $1.2 billion in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $1.2 billion through Sep 2025, changed N/A year-over-year, with the annual reading at $1.2 billion for FY2024, N/A changed from the prior year.
  • Notes Payables for Q3 2025 was $1.2 billion at Dexcom, roughly flat from $1.2 billion in the prior quarter.
  • The five-year high for Notes Payables was $1.2 billion in Q3 2025, with the low at $124.2 million in Q3 2023.
  • Average Notes Payables over 4 years is $908.3 million, with a median of $989.1 million recorded in 2023.